Mesenchymal stromal cell secretome in liver failure: Perspectives on COVID-19 infection treatment

Table 1 List of registered clinical trials on the use of mesenchymal stromal cell-derived extracellular vesicles for tissue injury

Tissue injury disease	Condition	Treatment	Trial ID	Status
Chronic lung disease	Pediatric bronchopulmonary dysplasia	BM-MSC-derived EVs	NCT03857841	Phase I
Lung disease	Pneumonia, COVID-19	BM-MSC-derived EVs	NCT04493242	Not yet recruiting
Lung disease	Pneumonia, COVID-19	Inhalation of mesenchymal stem cell exosomes	NCT04276987	Phase I
Multiple organ failure	Multiple organ dysfunction syndrome	MSC exosomes	NCT04356300	Not yet recruiting
Lung disease	Pulmonary infection	MSC exosomes	NCT04544215	Recruiting
Dry eye	GVHD	UC-MSC exosomes	NCT04213248	Recruiting
Cartilage injury	Osteoarthritis	Secretome or EVs from adipose MSCs	NCT04223622	Not yet recruiting
Skin disease	Dystrophic epidermolysis bullosa	BM-MSC EVs	NCT04173650	Phase II
Brain	Cerebrovascular disorders	Allogenic MSCs enriched with miR-124	NCT03384433	Phase II

BM: Bone marrow; COVID-19: Coronavirus disease 2019; EV: Extracellular vesicle; GVHD: Graft-vs-host disease; MSC: Mesenchymal stromal cell; UC: Umbilical cord.